A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes

Sponsor
Boehringer Ingelheim
Study ID
NCT03993132
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The primary research question is to evaluate whether, among patients with type 2 diabetes mellitus (T2D), initiation of empagliflozin changes the adjusted incidence of outcomes compared with initiation of Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA).

Key Dates

Start date
Oct 1, 2018
Status verified
Jun 2023
Primary completion
Jun 16, 2022
Completion
Jun 16, 2022

Study Design

Enrollment
26,774 participants (actual)

Arms

  • Arm: Patients with type 2 diabetes

Primary Outcome Measure

Incidence Rate of Expanded Major Adverse Cardiovascular Event (MACE) Composite Outcome - OT Analysis [ Time Frame: From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years. ]

Related Studies